All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Top Biopharma Trends of 2021
    • Top Med-tech Trends of 2021
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, June 30, 2022
Home » Topics » Newco news

Newco news
Newco news RSS Feed RSS

Test tubes, dropper and capsules
Newco news

Acesis Biomed takes on hypogonadism with testosterone replacement therapy

April 1, 2022
By Richard Staines
No Comments
Back in 2015, a black box warning from the U.S. FDA about the cardiovascular risks of testosterone therapy products caused a major upheaval in the market.
Read More
Newco news

On heels of $70M series B round, China’s Medilink Therapeutics poised to enter clinic with ADC pipeline

March 29, 2022
By Tamra Sami
No Comments
After securing $70 million in series B funding, Chinese biotech Medilink Therapeutics Co. Ltd. is gearing up to enter the clinic with its next-generation antibody-drug conjugates (ADCs).
Read More
Brain illustration
Newco news

Ninnion forms SAB to navigate 'uncharted waters' of psychedelics development

March 29, 2022
By Michael Fitzhugh
No Comments
Ninnion LLC, a startup developing psychedelic medicines focused on brain injury, chronic pain, inflammation and addiction disorders, has formed a new scientific board (SAB) that Chief Development Officer Bill Massey said will ”be a tremendous asset in navigating the uncharted waters of psychedelic drug development."
Read More
Antibody-drug conjugate
Newco news

On heels of $70M series B round, China’s Medilink Therapeutics poised to enter clinic with ADC pipeline

March 28, 2022
By Tamra Sami
No Comments
After securing $70 million in series B funding, Chinese biotech Medilink Therapeutics Co. Ltd. is gearing up to enter the clinic with its next-generation antibody-drug conjugates (ADCs).
Read More
Skin exam
Newco news

Moonlake going after blockbuster indications with dual-targeting nanobody

March 25, 2022
By Nuala Moran
No Comments
Moonlake Therapeutics AG is making headway on its mission to establish a broad dermatology and rheumatology franchise around its sole product, sonelokimab, announcing it is poised to start a phase II study in hidradenitis suppurativa.
Read More
Eric Leire, CEO, Genflow
Newco news

Genflow seeks an opening in active anti-aging market

March 16, 2022
By Richard Staines
No Comments
Biotechs that tackle the effects of aging are beginning to make headlines: in January Altos Labs Inc. launched with a reported investment from Jeff Bezos. With Bezos getting involved with San Francisco-based Altos, the immediate reaction was that anti-aging biotechs would be there for the benefit of billionaires searching for eternal life. Not so, according to London U.K.-based Genflow Biosciences plc, which hopes to show that fighting aging is really about improving health as people age.
Read More
Cancer cell
Newco news

Activating activators is strategy against apoptosis defectors

March 15, 2022
By Anette Breindl
No Comments
By combining an activator of the pro-apoptotic protein Bax with an inhibitor of the anti-apoptotic protein BCL-XL, researchers at Albert Einstein College of Medicine have been able to overcome resistance to apoptosis in both a wide range of cell lines and animal studies. The team reported its findings in the March 7, 2022, issue of Nature Communications.
Read More
Elderly hands holding broken brain structure
Newco news

Aevisbio and NIH work to tackle neuroinflammation in Alzheimer's disease

March 8, 2022
By David Ho
No Comments
A new study from researchers at Aevisbio Inc. and the National Institutes of Health on the effect of 3,6’-dithiopomalidomide on neuroinflammation adds new detail to what might one day become a significant new therapeutic strategy to treat Alzheimer's disease and other neurological disorders.
Read More
neal-fowler-3-4

Pathalys launches with in-licensed CKD drug upacicalcet ready for phase III

March 4, 2022
By Richard Staines
No Comments
Pathalys Pharma Inc., a privately held startup focused on developing new medicines chronic kidney disease, has emerged with an exclusive license from Tokyo-based EA Pharma Co. Ltd. to develop the small molecule calcimimetic upacicalcet for markets outside of Japan and Asia.
Read More
Red rocket launch button on keyboard

Vesalius launches to find the underlying causes of disease

March 2, 2022
By Lee Landenberger
No Comments
After two years of developing its platform, Vesalius Therapeutics Inc. now has $75 million in its pocket from Flagship Pioneering to understand and treat the diseases that account for 90% of the world’s illnesses. To resolve this massive amount of biological and industry complexity, Doug Cole, Vesalius’ chairman and co-founder and Flagship’s managing partner, noted the distinction between illness and disease. “Illness is what bothers you, it’s the experience of being sick and what the doctor might find when you’re examined,” Cole told BioWorld. “Disease is the mechanistic problem with the biology underlying the illness.”
Read More
Previous 1 2 3 4 5 6 7 8 9 … 29 30 Next

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 29, 2022.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech's briefs for June 29.
  • Enhertu.png

    Swing low, sweet Enhertu: Astrazeneca, Daiichi ASCO data carry HER2 message home

    BioWorld
    The “showdown” at the American Society of Clinical Oncology (ASCO) meeting foreseen by one analyst between breast cancer drugs from Gilead Sciences Inc. and...
  • Novavax-COVID-19-vaccine-vial

    Novavax vaccine shows its chops

    BioWorld
    Given that Novavax Inc.’s COVID-19 vaccine will be a latecomer to the U.S. scene if it gets FDA authorization, it’s been cast in a supporting role to the lead...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Archives
    • Today's news
    • Search BioWorld Science
    • About
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing